To assess the efficacy of very low-dose rATG (1.5 mg/kg) in low immunologic risk living related kidney transplant recipients (KTRs)
Latest Information Update: 29 May 2020
At a glance
- Drugs Antithymocyte globulin (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
Most Recent Events
- 29 May 2020 New trial record
- 12 May 2020 Results published in the Transplantation Proceedings